Free Trial
OTCMKTS:APLIF

Appili Therapeutics (APLIF) Stock Price, News & Analysis

Appili Therapeutics logo
$0.03
0.00 (0.00%)
(As of 10/31/2024 ET)

About Appili Therapeutics Stock (OTCMKTS:APLIF)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.05
Volume
895 shs
Average Volume
162,202 shs
Market Capitalization
$3.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Appili Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
15th Percentile Overall Score

APLIF MarketRank™: 

Appili Therapeutics scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Appili Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Appili Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Appili Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Appili Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Appili Therapeutics has recently decreased by 99.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Appili Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Appili Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Appili Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Appili Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Appili Therapeutics has recently decreased by 99.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Appili Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Appili Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Appili Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.84% of the stock of Appili Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Appili Therapeutics' insider trading history.
Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Appili Therapeutics – Press Release Correction
Appili Therapeutics Inc (APLI)
See More Headlines

APLIF Stock Analysis - Frequently Asked Questions

Appili Therapeutics' stock was trading at $0.0265 on January 1st, 2024. Since then, APLIF stock has increased by 4.2% and is now trading at $0.0276.
View the best growth stocks for 2024 here
.

Appili Therapeutics Inc. (OTCMKTS:APLIF) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01).

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/13/2024
Today
10/31/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:APLIF
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-2,800,000.00
Net Margins
-450.64%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$630,000.00
Book Value
($0.05) per share

Miscellaneous

Free Float
106,908,000
Market Cap
$3.35 million
Optionable
Not Optionable
Beta
-0.48
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (OTCMKTS:APLIF) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners